Biacore X100 is designed to enable new users to run successful assays from day one. PhD student and protein interaction analysis novice, Thuy Tran, put this theory to the test.
Research goal:
•
Compare binding of several Affibody® molecules to HER2
•
Determine binding specificity, affinity and on/off rates
Specificity of Affibody molecules rapidly defined
•
Thuy rapidly demonstrated binding specificity for all Affibody molecules
•
Compared binding levels to immobilized HER2 and a reference protein
Straightforward analysis of high affinity binders using single cycle kinetics
•
Standard kinetic assays analyze a different concentration of sample in successive cycles and any remaining bound sample must be completely removed by regeneration of the surface
•
Good regeneration conditions could not be found for the very high affinity variants, but Thuy used regeneration-free, single-cycle kinetics to easily and quickly acquire the data
Case study Mercodia AB
Biacore X100 in commercial biotechnology
Mercodia AB (Uppsala, Sweden) provide high quality immunoassay kits (ELISAs) for clinical and research use. These are used in human and other mammalian models in the fields of cardiovascular disease, obesity and diabetes.
Label-free characterization of antibody-antigen interactions provides important, high quality data for decision-making during product development and production in this type of biotechnology environment.
Characterization of antibody binding to target antigens makes valuable contributions to multiple aspects of Mercodia's workflow. Eleni Karamihos kindly shared her experiences with us after working with Biacore X100:
We gratefully acknowledge Eleni Karamihos, Robert Gunnarsson and Patrik Lindstedt (Mercodia AB) for their contributions.
Choose your destination
